Yissum - Research Development Company of the Hebrew University

5-MER Peptide to Ameliorate Coronavirus-Induced Inflammation of the Upper Respiratory Tract and Lungs

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

5-MER Peptide to Ameliorate Coronavirus-Induced Inflammation of the Upper Respiratory Tract and Lungs
Project ID : 47-2020-10890

Description of the technology

This study will test the hypothesis that treatment with a peptide comprising five units (5-MER), which is administered by injection or oral delivery, will substantially reduce chronic inflammation of the upper respiratory tract and lungs, thus ameliorating the effects of the Coronavirus disease. This will be achieved by targeting a major pro-inflammatory protein called SAA which plays an active role in the development of the disease. Furthermore, it is anticipated that the 5-MER peptide may also activate genes that provide resistance to chronic inflammation mediated by Coronavirus.

Prof. Naor’s research is based on his lab’s finding that a synthetic very short peptide, substantially reduced inflammation in models of rheumatoid arthritis, inflammatory bowel diseases and multiple sclerosis. Studies in his lab point to Serum Amyloid A (SAA) as the target for this peptide, which is also capable of activating genes that may contribute to resistance against chronic inflammations. In SARS, the previous Coronavirus global epidemic disease, SAA was found to increase significantly and was proposed as a suitable marker for the disease. The Naor lab has already shown the 5-MER peptide inhibits inflamed tissues stimulated with SAA.

Project manager

Keren-Or Amar
VP, Business Development, Healthcare

Project researchers

David Naor
HUJI, School of Medicine - IMRIC
Immunology and Cancer Research

Related keywords

  • Biological Sciences
  • Virus, Virology / Antibiotics / Bacteriology
  • Infectious Diseases
  • Covid-19
  • covid-19
  • coronavirus
  • respiratory
  • inflammation

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.